CLDN10

Across TCGA pan-cancer cohorts, CLDN10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLDN10 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CLDN10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN10 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, LUSC, and UCEC are the cancer types where CLDN10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUSC	OS	Median	II,III,IV	0.140	0.743	.001	24	view →
UCEC	DFS	Median	II,III,IV	0.922	0.435	.022	12	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLDN10–THYM (OS)

Open the THYM breakdown →